federal_register: 2013-19004

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
2013-19004 Guidance for Industry on Oversight of Clinical Investigations-A Risk-Based Approach to Monitoring; Availability Notice The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled "Oversight of Clinical Investigations--A Risk-Based Approach to Monitoring." This guidance assists sponsors in developing risk-based monitoring strategies and plans for clinical investigations of human drugs, biologics, medical devices, and combinations thereof. The overarching goal of this guidance is to enhance human subject protection and the quality of clinical trial data by focusing sponsor oversight on the most important aspects of study conduct and reporting. The guidance makes clear that sponsors can use a variety of approaches to meet their responsibilities for monitoring investigational new drug or investigational device exemption studies. 2013-08-07 2013 8 https://www.federalregister.gov/documents/2013/08/07/2013-19004/guidance-for-industry-on-oversight-of-clinical-investigations-a-risk-based-approach-to-monitoring https://www.govinfo.gov/content/pkg/FR-2013-08-07/pdf/2013-19004.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled "Oversight of Clinical Investigations--A Risk-Based Approach to Monitoring." This guidance assists sponsors in developing risk-based monitoring...  

Links from other tables